Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Noushin Brealey"'
Autor:
Peter R. Bremner, Ruby Birk, Noushin Brealey, Afisi S. Ismaila, Chang-Qing Zhu, David A. Lipson
Publikováno v:
Respiratory Research, Vol 19, Iss 1, Pp 1-10 (2018)
Abstract Background Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obs
Externí odkaz:
https://doaj.org/article/ccd29838d82b4091a09d185b46fc79d5
Autor:
Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson, Gerard Criner
Publikováno v:
ERJ Open Research, Vol 4, Iss 4 (2018)
Clinically important deterioration (CID) is a novel composite end-point (lung function, health status, exacerbations) for assessing disease stability in patients with chronic obstructive pulmonary disease (COPD). We prospectively analysed CID in the
Externí odkaz:
https://doaj.org/article/1c24a94a5bb24daeb8ac4f1810b76339
Autor:
David M.G. Halpin, Ruby Birk, Noushin Brealey, Gerard J. Criner, Mark T. Dransfield, Emma Hilton, David A. Lomas, Chang-Qing Zhu, David A. Lipson
Publikováno v:
ERJ Open Research, Vol 4, Iss 2 (2018)
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the b
Externí odkaz:
https://doaj.org/article/1dc7064705e44d09904b25cafb551f4a
Publikováno v:
European journal of endocrinology. 187(3)
Objective The aim of this study was toidentify dose-related systemic effects of inhaled glucocorticoids (GCs) on the global metabolome. Design and methods Metabolomics/lipidomic analysis from plasma was obtained from 54 subjects receiving weekly esca
Autor:
Dave Singh, Noushin Brealey, Peter T. Daley-Yates, Brian Keppler, Shaila S. Shabbir, Neil Barnes
Publikováno v:
Airway pharmacology and treatment.
This is the first study to compare the relative systemic metabolomic and lipidomic bioactivity dose-responses for ICS. Plasma for metabolomic and lipidomic analysis was obtained from 54 subjects (GSK study 203162, NCT02991859) who received weekly esc
Publikováno v:
Advances in Therapy
Introduction Few studies have utilized 24-h serial spirometry to compare the effects of inhaled chronic obstructive pulmonary disease (COPD) therapies on lung function. The FULFIL study previously reported significant lung function improvements with
Autor:
Daren Austin, Shaila S. Shabbir, Dave Singh, Neil Barnes, Peter T. Daley-Yates, Tim Harrison, Noushin Brealey, Sebin Thomas, B. Kumar
Publikováno v:
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..
Autor:
Neil Barnes, Tim Harrison, Daren Austin, Dave Singh, Sebin Thomas, Noushin Brealey, Peter T. Daley-Yates, Shaila S. Shabbir
Publikováno v:
British journal of clinical pharmacology. 87(2)
Aims To compare the airway potency, systemic activity and therapeutic index of three inhaled corticosteroids that differ in glucocorticoid receptor binding affinity, physicochemical and pharmacokinetic properties. Methods This escalating-dose, placeb
Autor:
Noushin Brealey, Steve Pascoe, Chang-Qing Zhu, Ruby Birk, Nicholas Locantore, David A. Lomas, David A. Lipson, Maggie Tabberer
Publikováno v:
Advances in Therapy
Introduction Directly recorded patient experience of symptoms and health-related quality of life (HRQoL) can complement lung function and exacerbation rate data in chronic obstructive pulmonary disease (COPD) clinical studies. The FULFIL study record
Autor:
David A. Lomas, Nicholas Locantore, Steven Pascoe, Andrea Ludwig-Sengpiel, Noushin Brealey, David A. Lipson, Ruby Birk, Chang-Qing Zhu, Helen Barnacle, Maggie Tabberer, Rajat Mohindra
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 196:438-446
Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.Objectives: We compared the effects of once-da